Better Buy: Celgene Corporation vs. Bristol-Myers Squibb
By most metrics, Celgene Corporation (NASDAQ: CELG) is smaller than Bristol-Myers Squibb (NYSE: BMY). Celgene has fewer employees, lower revenue, and lower earnings than BMS does. In one key way, though, Celgene is the bigger drugmaker: Its market cap is greater by several billion dollars.
This one outlier is a result of Celgene's tremendous stock performance. Shares have soared more than 250% in the past five years compared to BMS stock's gains of around 90% during the same period. But which of these two big pharma companies is the better choice for investors now? Here's how Celgene and Bristol-Myers Squibb stack up in several key areas.
Image source: Getty Images.
Source: Fool.com
Bristol-Myers Squibb Stock
€45.26
-2.070%
With 7 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 70 € shows a very positive potential of 54.66% compared to the current price of 45.26 € for Bristol-Myers Squibb.
